Shandong Lukang Pharmaceutical Co.,Ltd.: history, ownership, mission, how it works & makes money

Founded in Jining, Shandong in 1966, Shandong Lukang Pharmaceutical Co., Ltd. (listed on the Shanghai Stock Exchange as 600789 since 1997) is a state-owned pharma group with total assets of 6.6 billion yuan, over 6,000 employees, a product portfolio exceeding 500 SKUs and annual exports of $150 million; the company operates 13 joint ownership enterprises (including five wholly owned subsidiaries and two joint ventures), runs internationally certified production lines (EU GMP, FDA, cGMP, Chinese GMP) with annual capacities of 150,000 tons of APIs, six billion oral solid FDFs and two billion vials of injectable powder, reports 2024 revenue of 6.23 billion yuan (up 1.41% year-on-year), holds national high-tech and provincial technology centers, and ranks in Shandong's Top 10 industrial clusters and 48th in the 2023 China Pharmaceutical Industry Top 100 List while being designated a national "Green Factory" and key export brand-revealing how history, ownership, certification, scale and a diversified API/FDF/export-led business model combine to drive its market position and financial performance

Shandong Lukang Pharmaceutical Co.,Ltd. (600789.SS): Intro

• Founded in 1966 in Jining, Shandong Province as a state-owned pharmaceutical manufacturer.
• Listed on the Shanghai Stock Exchange in 1997 under stock code 600789.SS, entering public capital markets.
• Expanded through decades into a diversified group with manufacturing, R&D and international trade capabilities.

• State-owned enterprise with multiple group-level holdings and subsidiaries.
• Group structure: 13 joint ownership enterprises comprising five wholly owned subsidiaries, six holding companies, and two joint ventures.

• Total assets (2023): ¥6.6 billion.
• Employees: over 6,000 staff (2023).
• Export reach: products sold to more than 50 countries and regions across Asia, Europe, Africa and the Americas; annual exports ≈ $150 million.

• More than 500 products spanning human and veterinary active pharmaceutical ingredients (APIs), finished dosage forms (FDFs), and agricultural chemicals.
• Customer base includes domestic hospitals, distributors, veterinary channels, agricultural customers and international pharmaceutical partners.

• API sales: Bulk supply to domestic and international generic and branded drug makers.
• Finished dosage forms (FDFs): Higher-margin finished products for hospitals, pharmacies and export markets.
• Veterinary products: Stable recurring revenue from animal health markets.
• Agricultural chemicals: Specialized agrochemicals sold to distributors and farms.
• Contract manufacturing and toll processing: Revenue from third-party manufacturing agreements.
• Exports and international contracts: Direct sales and long-term supply contracts generating ≈ $150M annually.

• Corporate mission focuses on improving human and animal health through reliable pharmaceutical and agrochemical products, supported by state ownership and long-term industrial capability.
• Strategic priorities include expanding higher-margin finished products, strengthening export markets, and leveraging joint ventures for specialty capabilities.
• For detailed corporate mission, vision and core values: Mission Statement, Vision, & Core Values (2026) of Shandong Lukang Pharmaceutical Co.,Ltd.

Shandong Lukang Pharmaceutical Co.,Ltd. (600789.SS): History

Shandong Lukang Pharmaceutical Co.,Ltd. (600789.SS) is a state-owned pharmaceutical enterprise with origins in Shandong province. Its modern corporate form and expansion were shaped by integration into larger state platforms and a network of subsidiaries and joint ventures that provide manufacturing, R&D, distribution and capital support.

• State ownership: Lukang Pharma is controlled as a state-owned enterprise, reflecting ultimate ownership and strategic guidance from government-related entities.
• Integration milestone: In 2006 the company became part of Hualu Holdings Co., Ltd., a major state-owned conglomerate, enhancing access to capital, procurement channels and technology platforms.
• Group network: The company now comprises 13 joint ownership enterprises - five wholly owned subsidiaries, six holding companies and two joint ventures - enabling specialization and regional reach.

• Resource leverage: The ownership structure allows Lukang to deploy capital, manufacturing capacity and distribution networks across subsidiaries and joint ventures to accelerate product commercialization.
• Strategic collaborations: Cross-holding arrangements with Hualu Holdings and other partners enable access to advanced production technologies, bulk procurement discounts and R&D partnerships.
• Risk diversification: Multiple legal entities (wholly owned, holding and JV formats) distribute operational and regulatory risk across the group while preserving centralized strategic control.

For a full chapter and extended treatment of history, mission and how the company makes money, see: Shandong Lukang Pharmaceutical Co.,Ltd.: History, Ownership, Mission, How It Works & Makes Money

Shandong Lukang Pharmaceutical Co.,Ltd. (600789.SS): Ownership Structure

• Mission and values: develop, manufacture and commercialize APIs and FDFs for human drugs, animal health and bio-pesticides with an emphasis on quality, safety and global accessibility.
• Quality management: adheres to international management systems and holds certifications including ISO 9001 (quality), ISO 14001 (environment) and ISO 45001 (occupational health & safety).
• Innovation & R&D: operates dedicated platforms such as the Shandong Industrial Biotechnology Transformation Platform and the Shandong University-Lukang Microbial Technology Research Institute to accelerate bioprocess development and microbial technology translation.
• Recognition: designated a national high‑tech enterprise and selected as a pilot enterprise for integration of industrialization and informatization under China's Ministry of Industry and Information Technology (MIIT).
• Strategic direction: committed to embracing new development phases, implementing innovative business concepts and building a new development framework to drive sustainable, high‑quality growth.

• API production: large-scale fermentation and chemical synthesis lines supply domestic and export customers (pharmaceutical manufacturers, veterinary drug makers and agrochemical companies).
• FDF manufacturing: formulation, tableting, and packaging for human and veterinary products sold under contract manufacturing and Lukang-branded lines.
• Animal health & bio-pesticides: products sold through dedicated sales channels and distributors for livestock, aquaculture and crop protection.
• R&D-driven product pipeline: licensing, registration and commercialization of new molecules and green manufacturing processes to capture higher-margin finished products.

• Listed on Shanghai Stock Exchange: ticker 600789.SS.
• Shareholder mix: combination of institutional investors, domestic strategic shareholders, management/team holdings and free-float retail investors.
• Board oversight: typical Chinese listed-company governance with board of directors, supervisory board and senior management responsible for operations, compliance and strategic R&D investments.

• Platforms: Shandong Industrial Biotechnology Transformation Platform; Shandong University-Lukang Microbial Technology Research Institute-these support process optimization, strain development, biocatalysis and downstream scale-up.
• Focus areas: fermentation-based APIs, green chemistry for synthesis, formulation improvements for FDFs, and veterinary/biopesticide product innovation.
• Outcomes: steady pipeline of generic-to-proprietary transitions, continuous process improvements to reduce cost and environmental footprint, and strengthened registration dossiers for export markets.

Shandong Lukang Pharmaceutical Co.,Ltd. (600789.SS): Mission and Values

• Listed on the Shanghai Stock Exchange (ticker: 600789.SS).
• Ownership comprises institutional investors, retail shareholders and corporate stakeholders; management and group affiliates retain strategic stakes to support long-term operations.
• Export footprint spans more than 50 countries and regions across Asia, Europe, Africa and the Americas, supporting annual export revenues of approximately $150 million.

• Six national high‑tech enterprises under the group and multiple provincial technology centers.
• One national-level enterprise technology center plus two Shandong provincial-level enterprise technology centers.
• Production facilities certified to international and domestic standards: EU GMP, FDA (where applicable), cGMP and Chinese GMP.
• Annual manufacturing capacity:
  • 150,000 tons of various APIs
  • 6 billion oral solid FDF units (tablets/capsules/bags)
  • 2 billion vials of powder for injection

• Shandong Industrial Biotechnology Transformation Platform - industrial-scale biotechnology R&D and technology transfer.
• Shandong University-Lukang Microbial Technology Research Institute - academic partnership for microbial processes and strain development.
• Multiple in‑house R&D labs and pilot plants enabling scale‑up from lab to commercial production.

• Product mix: bulk APIs, oral solid FDFs, injectables (powder for injection), and specialty intermediates.
• Revenue drivers: B2B API sales to domestic and global formulators, contract manufacturing, export sales (~$150M annually), and proprietary finished-dosage products for selected markets.
• Geographic diversification: customers in >50 countries across Asia, Europe, Africa and the Americas.

• Mission: deliver high‑quality, affordable pharmaceutical ingredients and formulations through innovation, scale and compliance.
• Values: regulatory compliance, technological innovation, manufacturing excellence, and global customer focus.
• Strategic focus: integrate industrialization and informatization to raise efficiency and product traceability across the value chain.

Shandong Lukang Pharmaceutical Co.,Ltd. (600789.SS): How It Works

• 2024 annual revenue: 6.23 billion yuan (a 1.41% increase vs. prior year)
• Primary revenue streams: APIs, FDFs, animal health products, bio-pesticides
• Export footprint: products sold to more than 50 countries and regions

• Diversified product portfolio serving human pharmaceuticals, veterinary medicine, and agricultural bio-solutions
• End-to-end manufacturing-from small-molecule API synthesis to finished dosage formulation and packaging
• Regulated-market compliance via internationally recognized facility certifications

• Designated a national high-tech enterprise
• Pilot enterprise for integration of industrialization and informatization under the Ministry of Industry and Information Technology
• Production facilities certified to EU GMP, FDA, cGMP, and Chinese GMP standards

• Domestic sales to hospitals, distributors, veterinary channels, and agricultural customers
• Export contracts and long-term supply agreements for APIs and finished products
• Value-added services: formulation development, contract manufacturing (CDMO-like activities), and regulatory support for export markets
• Leveraging certified facilities and high-tech status to compete in regulated markets and secure higher-margin contracts

• International certifications enabling access to EU/US regulated customers
• Product diversification across human, animal, and agricultural segments to reduce market concentration risk
• Export scale-presence in 50+ countries-providing foreign-currency and volume contribution to overall revenue
• Recognition and government-backed pilot status supporting digital/industrial upgrades that improve manufacturing efficiency

Shandong Lukang Pharmaceutical Co.,Ltd. (600789.SS): How It Makes Money

• Market position: Ranked 48th in the 2023 China Pharmaceutical Industry Top 100 List and recognized as a leader in Shandong Province's "Top 10" industrial clusters.
• National recognitions: Designated a national "Green Factory" by the Ministry of Industry and Information Technology and listed as a key export brand under the Ministry of Commerce.
• R&D & tech platforms: Operates multiple R&D platforms including the Shandong Industrial Biotechnology Transformation Platform and the Shandong University-Lukang Microbial Technology Research Institute.

• API production and sales - bulk active pharmaceutical ingredients manufactured for domestic and overseas formulators and generic producers.
• Finished dosage forms - prescription and OTC drugs supplied to hospitals, pharmacies, and distributors across China and select export markets.
• Biotech & specialty products - microbial fermentation products, biologics components and high‑margin specialty pharmaceuticals developed via in‑house biotech platforms.
• Contract manufacturing and OEM/ODM services - capacity utilization for third‑party customers domestically and internationally.
• R&D collaborations and licensing - milestone and royalty income from partnered pipelines and technology transfers.

• Innovation focus - targeted breakthroughs in innovative drugs, biotechnology applications and intelligent manufacturing to lift product mix and margins.
• Operational excellence - digitalization and performance management initiatives to raise capacity utilization and lower unit costs.
• Export expansion - leveraging key export‑brand status and Green Factory credentials to win overseas tenders and long‑term supply agreements.
• R&D scale - continued investment in in‑house platforms (e.g., Shandong Industrial Biotechnology Transformation Platform and Shandong University‑Lukang Microbial Technology Research Institute) to pipeline novel products and licensing opportunities.